Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) Depreciation & Amortization (CF): 2010-2024

Historic Depreciation & Amortization (CF) for EyePoint Pharmaceuticals (EYPT) over the last 15 years, with Dec 2024 value amounting to $1.5 million.

  • EyePoint Pharmaceuticals' Depreciation & Amortization (CF) rose 110.00% to $3,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $60,000, marking a year-over-year decrease of 57.14%. This contributed to the annual value of $1.5 million for FY2024, which is 208.00% up from last year.
  • EyePoint Pharmaceuticals' Depreciation & Amortization (CF) amounted to $1.5 million in FY2024, which was up 208.00% from $500,000 recorded in FY2023.
  • In the past 5 years, EyePoint Pharmaceuticals' Depreciation & Amortization (CF) ranged from a high of $1.5 million in FY2024 and a low of $189,000 during FY2020.
  • Its 3-year average for Depreciation & Amortization (CF) is $813,333, with a median of $500,000 in 2023.
  • Data for EyePoint Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY surged of 208.00% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows EyePoint Pharmaceuticals' Depreciation & Amortization (CF) stood at $189,000 in 2020, then skyrocketed by 64.55% to $311,000 in 2021, then rose by 28.62% to $400,000 in 2022, then increased by 25.00% to $500,000 in 2023, then spiked by 208.00% to $1.5 million in 2024.